Hong Kong suspended vaccinations using Pfizer shots known as BioNTech shots in the city on Wednesday after they were informed by its distributor Fosun that one batch had defective bottle lids.
The suspension was immediate while Chinese pharmaceutical firm Fosun Pharma and BioNTech, the German company which created the vaccine with American pharmaceutical firm Pfizer, investigate the matter, according to a statement by the Hong Kong government.
BioNTech and Fosun Pharma have not found any reason to believe the product is unsafe, according to the statement. However, vaccinations will be halted as a preventive and safety measure.
The defective lids were found on vaccines from batch number 210202. A separate batch of vaccines, 210104, will also be not be administered.
Macao also said Wednesday that residents would not receive the Pfizer vaccinations from the affected batch.
All community centers in Hong Kong administering the Pfizer vaccine have temporarily suspended vaccinations and residents who already made appointments for Wednesday need not proceed to the centers, the government said.
The suspension of the Pfizer jab means the only vaccine currently offered to residents is China's Sinovac vaccine. The two vaccines are the only ones that were offered to residents in Hong Kong.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU